1. Torres T. Selective interleukin-23 p19 inhibition: another game changer in psoriasis? Focus on risankizumab. Drugs. 2017;77(14):1493–503.
2. Haugh IM, Preston AK, Kivelevitch DN, et al. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Dev Ther. 2018;12:3879–83.
3. AbbVie. Risankizumab (Skyrizi): Japanese prescribing information. 2019.
http://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/39994C9
. Accessed 28 Mar 2019.
4. AbbVie. AbbVie announces first regulatory approval of SKYRIZI™ (risankizumab) for the treatment of plaque psoriasis, generalized pustular psoriasis and erythrodermic psoriasis and psoriatic arthritis in Japan [media release]. 26 Mar 2019.
https://news.abbvie.com
.
5. Abbvie. Health Canada approves SKYRIZI™ (risankizumab) for the treatment of moderate to severe plaque psoriasis [media release]. 18 Apr 2019.
http://www.abbvie.ca/
.